Immunome, Inc. (IMNM) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Immunome, Inc.
Address
18702 North Creek Parkway
Bothell, WA 98011
United States of America (the)
Phone
610 321 3700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
247
First IPO Date
October 02, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Clay Siegall | Chairman, President & Chief Executive Officer | 1.41M | 1961 |
| Kinney Horn | Chief Business Officer | 598,862 | 1975 |
| Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary | 715,350 | 1973 |
| Robert J. Lechleider | Chief Medical Officer | 850,093 | 1961 |
| Jack Higgins | Chief Scientific Officer | 956,342 | 1980 |
| Max Rosett | Chief Financial Officer | 1.16M | 1990 |
| Roee Shahar | Executive Vice President of Commercial | 0 | N/A |
| Philip Tsai | Chief Technical Officer | 0 | 1968 |
Description
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
